HHHans-Juergen Heidebrecht

Hans-Juergen Heidebrecht

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hans-Juergen Heidebrecht has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Reza Parwaresch

    Department of Pathology, Hematopathology and Lymph Node Registry, Schleswig-Holstein University Hospitals, Campus Kiel, Michaelisstrasse 11, 24105 Kiel, Germany

    4 shared publications
  • Friedrich Buck

    Institute for Clinical Chemistry, University of Hamburg, Hamburg, Germany; and

    3 shared publications
  • Marc Pollmann

    Department of Pathology, Hematopathology and Lymph Node Registry, Schleswig-Holstein University Hospitals, Campus Kiel, Michaelisstrasse 11, 24105 Kiel, Germany

    3 shared publications
  • Marie-Luise Kruse

    1st Department of Medicine, Schleswig-Holstein University Hospitals, Campus Kiel, Germany

    3 shared publications
  • Sabine Adam-Klages

    Department of Immunology, Schleswig-Holstein University Hospitals, Campus Kiel, Germany

    3 shared publications
  • Elmar Endl

    2 shared publications

Latest Publications

  • Open Access

    Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration

    by Anja Koop, Nadia Sellami, Sabine Adam-Klages, Marcus Lettau, Dieter Kabelitz, Ottmar Janssen, Hans-Jürgen Heidebrecht

    Background: Due to their restricted expression in male germ cells and certain tumors, cancer/testis (CT) antigens are regarded as promising targets for tumor therapy. CT45 is a recently identified nuclear CT antigen that was associated with a severe disease score in Hodgkin’s lymphoma and poor prognosis in multiple myeloma. As for many CT antigens, the biological function of CT45 in developing germ cells and in tumor cells is largely unknown. Methods: CT45 expression was down-regulated in CT45-positive Hodgkin’s lymphoma (L428), fibrosarcoma (HT1080) and myeloma (U266B1) cells using RNA interference. An efficient CT45 knock-down was confirmed by immunofluorescence staining and/or Western blotting. These cellular systems allowed us to analyze the impact of CT45 down-regulation on proliferation, cell cycle progression, morphology, adhesion, migration and invasive capacity of tumor cells. Results: Reduced levels of CT45 did not coincide with changes in cell cycle progression or proliferation. However, we observed alterations in cell adherence, morphology and migration/invasion after CT45 down-regulation. Significant changes in the distribution of cytoskeleton-associated proteins were detected by confocal imaging. Changes in cell adherence were recorded in real-time using the xCelligence system with control and siRNA-treated cells. Altered migratory and invasive capacity of CT45 siRNA-treated cells were visualized in 3D migration and invasion assays. Moreover, we found that CT45 down-regulation altered the level of the heterogeneous nuclear ribonucleoprotein syncrip (hnRNP-Q1) which is known to be involved in the control of focal adhesion formation and cell motility. Conclusions: Providing first evidence of a cell biological function of CT45, we suggest that this cancer/testis antigen is involved in the modulation of cell morphology, cell adherence and cell motility. Enhanced motility and/or invasiveness of CT45-positive cells could contribute to the more severe disease progression that is correlated to CT45-positivity in several malignancies.


  • Regulation of repp86 stability by human Siah2

    by Monika Szczepanowski, Sabine Adam-Klages, Marie-Luise Kruse, Marc Pollmann, Wolfram Klapper, Reza Parwaresch, Hans-Juergen Heidebrecht


  • Open Access

    Characterization and Expression of CT45 in Hodgkin's Lymphoma

    by Hans-Jürgen Heidebrecht, Alexander Claviez, Marie Luise Kruse, Marc Pollmann, Friedrich Buck, Sönke Harder, Markus Tiemann, Wolfgang Dörffel, Reza Parwaresch

    Purpose: The monoclonal antibody Ki-A10 (IgG1) generated after immunization of mice with Hodgkin's lymphoma cell line L428 detects a nuclear antigen in human tissues with a restricted distribution pattern similar to cancer/testis antigens. The aim of this study was to characterize the antigen and to determine the expression profile in Hodgkin's lymphoma.


    • 1 February 2003
      • Vol. 1  (4) , 271-9

    repp86: A human protein associated in the progression of mitosis.

    by Hans-Juergen Heidebrecht, Sabine Adam-Klages, Monika Szczepanowski, Marc Pollmann, Friedrich Buck, Elmar Endl, Marie-Luise Kruse, Pierre Rudolph, Reza Parwaresch

    Human repp86 becomes detectable in the nucleoplasm of cycling cells at the G(1)-S boundary, condenses at the centrosomes with the onset of mitosis, during which it progressively locates to the mitotic spindle and to the midbody, and vanishes at the completion of cytokinesis. The repp86 cDNA was cloned and sequenced. Full-length repp86 and its COOH-terminal domain cosediment with polymerized microtubules, linking repp86 to the family of microtubule-associated proteins. During prophase and metaphase, repp86 interacts on the mitotic spindle with the putative motor protein Hklp2. Thus, repp86 may function in targeting Hklp2 to the microtubule minus ends, its activity being regulated by phosphorylation of serine/threonine residues. Exogenous overexpression of repp86 provokes accumulation of cells in G(2)-M phase and subsequent polyploidization, suggesting that excess repp86 may interfere with correct nuclear division.


  • Open Access

    Ki-Mcm6, a New Monoclonal Antibody Specific to Mcm6: Comparison of the Distribution Profile of Mcm6 and the Ki-67 Antigen

    by Hans-Jürgen Heidebrecht, Friedrich Buck, Elmar Endl, Marie-Luise Kruse, Sabine Adam-Klages, Kristine Andersen, Sven Olaf Frahm, Christoph Schulte, Hans Heinrich Wacker, Reza Parwaresch


  • Cloning and Localization of C2orf2ropp120, A Previously Unknown WD Repeat Protein

    by H.J. Heidebrecht, F. Buck, M. Pollmann, R. Siebert, R. Parwaresch